Medtronic PLC $MDT Shares Sold by Orange Investment Advisors Inc.

Orange Investment Advisors Inc. reduced its position in Medtronic PLC (NYSE:MDT) by 5.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,692 shares of the medical technology company’s stock after selling 6,000 shares during the period. Medtronic comprises about 1.0% of Orange Investment Advisors Inc.’s portfolio, making the stock its 27th biggest holding. Orange Investment Advisors Inc.’s holdings in Medtronic were worth $8,257,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in MDT. BlackRock Inc. grew its position in Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after buying an additional 838,220 shares during the period. State Street Corp increased its holdings in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after buying an additional 1,658,301 shares in the last quarter. Bank of America Corp DE increased its holdings in Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after buying an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after buying an additional 3,739,288 shares in the last quarter. Finally, WCM Investment Management LLC acquired a new position in shares of Medtronic in the first quarter worth about $965,922,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MDT shares. TD Cowen reissued a “buy” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, September 30th. Truist Financial restated a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Evercore set a $105.00 price target on Medtronic in a research note on Monday, July 6th. Bank of America upped their price target on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Finally, Mizuho set a $115.00 price target on Medtronic in a report on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.

Medtronic Price Performance

Medtronic stock opened at $95.48 on Monday. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The firm has a market capitalization of $122.13 billion, a price-to-earnings ratio of 23.52, a PEG ratio of 2.23 and a beta of 0.55. The company has a fifty day simple moving average of $91.43 and a 200-day simple moving average of $85.29. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were issued a $0.72 dividend. The ex-dividend date was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares of the company’s stock, valued at $10,167,936. This trade represents a 8.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the transaction, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 61,903 shares of company stock worth $5,889,203. Insiders own 0.27% of the company’s stock.

Medtronic Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.